姜黄素治疗冠状病毒病2019感染的研究进展

An updated review of therapeutic effects of curcumin against COVID-19 infection

冠状病毒病2019(COVID-19)是由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)导致的疾病,目前该病毒的流行仍未得到良好控制。因此,深入分析该病毒感染的病理生理学特点并研发潜在的治疗药物的需求十分迫切。姜黄素作为植物提取物,已有研究证实其具有抗炎、抗肿瘤及抗氧化的特性,可帮助改善多种呼吸道症状,降低胃肠道系统的炎症反应,具有抗凝血功能,可作为治疗COVID-19的潜在药物。因姜黄素生物利用度较低,临床试验中通过使用纳米递送系统,使用佐剂,使用新剂型等策略来提高口服姜黄素的生物利用度。本文旨在探讨姜黄素的作用机制及药用潜力,汇总目前姜黄素治疗COVID-19的临床研究现状,以期为后续研究和开发治疗COVID-19的姜黄素制剂提供参考。

Corona Virus Disease 2019(COVID-19), caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), remains a global challenge with inadequate control of its spread. Consequently, there is an urgent need to comprehensively analyze the pathophysiological characteristics of this viral infection and develop potential therapeutic interventions. Curcumin, a plant-derived compound, has been studied extensively and shown to possess anti-inflammatory, anti-tumor, and antioxidant properties. It can help alleviate various respiratory symptoms, reduce gastrointestinal inflammation, and exhibit anticoagulant effects, making it a potential candidate for COVID-19 treatment. However, curcumin's low bioavailability necessitates strategies such as nanodelivery systems, adjuvants, and novel formulations to enhance its oral absorption in clinical trials. This article aims to explore the mechanisms of action and medicinal potential of curcumin, summarize the current status of clinical research on curcumin in COVID-19 treatment, and provide insights for future studies and the development of curcumin formulations for COVID-19 therapy.